 |
|
|
| |
A Real-World Observational Study on Patients With HIV Who Switched From Nevirapine + 2 Nucleoside
Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada
|
| |
| |
IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC
Joseph J. de Wet,1,2 Joann K. Ban,3 Gustavo Verdier,4 Juejing Ling,5 Maria Eberg,5 Andrean Bunko,5 Michael McKimm4
1Spectrum Health, Vancouver, British Columbia, Canada; 2Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada; 3GSK, Mississauga, Ontario, Canada; 4ViiV Healthcare, Montréal, Québec, Canada; 5IQVIA, Kirkland, Québec, Canada
|
| |
|
|
|
|
|
